Company Filing History:
Years Active: 1996-2002
Title: Yury Lagoviyer: Innovator in Pharmaceutical Technology
Introduction
Yury Lagoviyer is a notable inventor based in St. Louis, MO (US), recognized for his contributions to pharmaceutical technology. He holds three patents that showcase his innovative approach to creating effective medicinal formulations. His work has significant implications for the development of rapidly disintegratable tablets, which can enhance patient compliance and treatment efficacy.
Latest Patents
One of Yury Lagoviyer's latest patents is focused on a means for creating a mass having structural integrity. This invention includes a rapidly disintegratable tablet designed for administration with or without water. The tablet comprises at least one active ingredient and a mixture of excipients that provide desired characteristics and physical properties. When the tablet is sintered or heated, it exhibits excellent binding characteristics. The process for preparing this tablet involves dissolving bulking and structural agents in a suitable solvent, spray-drying or dispersing the mixture to obtain a granulated product, and compressing it to achieve the final formulation. This innovative approach has a wide variety of applications in the pharmaceutical industry.
Career Highlights
Throughout his career, Yury Lagoviyer has worked with prominent companies in the pharmaceutical sector, including Drugtech Corporation and K.V. Pharmaceutical Company. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in drug formulation technologies.
Collaborations
Yury has collaborated with notable professionals in the field, including R Saul Levinson and Thomas C Riley. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Yury Lagoviyer's work in developing rapidly disintegratable tablets represents a significant advancement in pharmaceutical technology. His innovative patents and collaborations highlight his commitment to improving drug delivery systems. His contributions continue to influence the industry and enhance patient care.